Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
138 hedge funds and large institutions have $1.18B invested in Acceleron Pharma in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 45 reducing their positions, and 15 closing their positions.
16% more capital invested
Capital invested by funds: $1.02B → $1.18B (+$162M)
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
1% more funds holding
Funds holding: 136 → 138 (+2)
2% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 45
18% less call options, than puts
Call options by funds: $2.19M | Put options by funds: $2.68M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$25.3M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$22.9M |
| 3 |
Goldman Sachs
New York
|
+$13.9M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.6M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$9.94M |
Top Sellers
XLRN Hedge Fund Activity: Q3 2016 in Review
138 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2016, worth a combined $1.18B — up 16% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XLRN positions and 15 closed out — a net gain of 2 holders — while 46 added to existing stakes and 45 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $25.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $12.6M sold.
- 138 institutional investors held Acceleron Pharma (XLRN) as of Q3 2016, up from 136 in Q2 2016.
- Funds reported $1.18B of Acceleron Pharma stock for Q3 2016, up 16% quarter-over-quarter.
- 17 funds opened new Acceleron Pharma positions in Q3 2016 and 15 closed out, a net change of +2 holders.
- The largest Acceleron Pharma buyer in Q3 2016 was Morgan Stanley, an estimated $25.3M added.
- The largest Acceleron Pharma seller in Q3 2016 was EcoR1 Capital, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2016.